OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Investigator: Scott Sneddon

1 Projects | 1 Researchers | $188,800 Invested

2014

Sharp Edge Labs, Inc

Scott Sneddon, PhD, JD

FTD Trafficking Assays and Compound Screening: Inhibiting Sortilin-dependent progranulin endocytosis.

  • Funding Amount: $188,800
  • Organization Type: Biotechnology/For Profit
  • Program: Drug Discovery
  • Target: TDP-43
  • Status: Closed